Both unloaded and exenatide-loaded lipid nanocapsules exerted a pronounced effect on glucose homeostasis and insulin resistance compared to the other treatment groups, in the two animal models of early NASH studied, demonstrating that the observed effect is not model specific. Here, INS is linked to metabolic dysfunction-associated steatohepatitis.